The Baveno VII consensus workshop has provided several novel recommendations regarding the management of patients with clinically significant portal hypertension (CSPH). The expert panel summarized the existing data into simple clinical rules to aid clinicians in their clinical practice. The use of non-invasive tests (NITs), especially liver stiffness measurement (LSM), have gain an important role in daily practice. The use of LSM alone or in combination with platelet count can be used to rule-in and rule-out compensated advanced chronic liver disease (cACLD) and CSPH. Further decompensation events were defined as a prognostic stage associated with an even higher mortality than that associated with first decompensation. Moreover, the term hepatic recompensation was introduced in Baveno VII consensus implying a partial or complete regression of the functional and structural changes of cirrhosis after the removal of the underlying etiology. This review will summarize the reader main aspects of Baveno VII consensus regarding the use of NITs in cACLD, analyze further decompensation events, and evaluate recent recommendations for prophylaxis and management of liver decompensation events.

Baveno VII 共识研讨会就临床显着门脉高压 (CSPH) 患者的治疗提供了几项新颖的建议。专家组将现有数据总结为简单的临床规则，以帮助临床医生进行临床实践。无创测试（NIT）的使用，特别是肝脏硬度测量（LSM），在日常实践中发挥着重要作用。单独使用 LSM 或与血小板计数结合使用可用于排除和排除代偿性晚期慢性肝病 (cACLD) 和 CSPH。进一步失代偿事件被定义为与首次失代偿相关的死亡率更高相关的预后阶段。此外，Baveno VII共识中引入了术语“肝脏再代偿”，这意味着在消除潜在病因后，肝硬化的功能和结构变化部分或完全消退。本综述将总结读者关于在 cACLD 中使用 NIT 的 Baveno VII 共识的主要方面，进一步分析失代偿事件，并评估最近关于预防和管理肝脏失代偿事件的建议。